Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Miriam Paone
Observed names:
M Paone,
M. Paone,
Paone, Miriam
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institutions:
University of Tokyo Hospital,
Hospitales Nisa,
Institute of Biostructure and Bioimaging,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Istituto di Chimica Biomolecolare,
National Research Council
show all 6
ORCID:
0000-0002-6913-3456
Observed ORCID:
0000-0002-6913-3456
OpenAlex ID:
A5020521265
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
2018
·
Mariaelena Capone
, Diana Giannarelli
, et al.
·
Journal for ImmunoTherapy of Cancer
·
542
PDF
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
2014
·
Antonio M Grimaldi
, Ester Simeone
, et al.
·
OncoImmunology
·
396
PDF
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
2014
·
Ester Simeone
, Giusy Gentilcore
, et al.
·
Cancer Immunology Immunotherapy
·
267
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
2024
·
Paolo A. Ascierto
, Milena Casula
, et al.
·
Nature Communications
·
111
PDF
Serious haematological toxicity during and after ipilimumab treatment: a case series
2014
·
Ester Simeone
, Antonio Maria Grimaldi
, et al.
·
Journal of Medical Case Reports
·
57
PDF
Rossinone-related meroterpenes from the Antarctic ascidian Aplidium fuegiense
2012
·
Marianna Carbone
, Laura Núñez-Pons
, et al.
·
Tetrahedron
·
47
The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era
2019
·
Vito Vanella
, Lucia Festino
, et al.
·
Current Oncology Reports
·
28
Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization
2022
·
Domenico Mallardo
, Ester Simeone
, et al.
·
Journal of Translational Medicine
·
24
PDF
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma
2024
·
Paolo A. Ascierto
, Mario Mandalà
, et al.
·
NEJM Evidence
·
21
PDF
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
2023
·
Salvatore Alfieri
, Rebecca Romanò
, et al.
·
The Oncologist
·
10
PDF
ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma
2024
·
Domenico Mallardo
, Mario Fordellone
, et al.
·
International Journal of Molecular Sciences
·
8
PDF
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
2023
·
Paolo A. Ascierto
, Eleonora Cioli
, et al.
·
Frontiers in Oncology
·
4
PDF
Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
2014
·
Ester Simeone
, Giusy Gentilcore
, et al.
·
Cancer Immunology Immunotherapy
·
4
PDF
Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
2014
·
Antonio M Grimaldi
, Ester Simeone
, et al.
·
Journal of Translational Medicine
·
4
PDF
The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
2013
·
Antonio M Grimaldi
, Ester Simeone
, et al.
·
Journal for ImmunoTherapy of Cancer
·
4
PDF
International real-world study of combination immunotherapy sequences in metastatic melanoma
2025
·
Mora Guardamagna
, Sarah E Lochrin
, et al.
·
Journal for ImmunoTherapy of Cancer
·
3
PDF
Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.
2024
·
Paolo Antonio Ascierto
, Pietro Quaglino
, et al.
·
Journal of Clinical Oncology
·
3
Corrigendum to “Rossinone-related meroterpenes from the Antarctic ascidian Aplidium fuegiense” [Tetrahedron 68 (2012) 3541–3544]
2012
·
Marianna Carbone
, Laura Núñez-Pons
, et al.
·
Tetrahedron
·
3
Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
2015
·
Ester Simeone
, Antonio Grimaldi
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
A multicenter, randomized phase Ib trial to evaluate neoadjuvant immunotherapy combination of nivolumab alone or plus ipilimumab with the IL-2 superkine MDNA11 alone or with tocilizumab in patients with high-risk, surgically resectable melanoma: The NEO-CYT trial.
2026
·
Margaret Ottaviano
, Domenico Mallardo
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer
2026
·
Vincenzo Quagliariello
, Margherita Passariello
, et al.
·
Journal of Cardiovascular Pharmacology
·
1
Impact of sex on immune-related adverse events in patients with melanoma.
2024
·
Margaret Ottaviano
, Domenico Mallardo
, et al.
·
Journal of Clinical Oncology
·
1
PDF
EP-1392: The abscopal effect:efficacy of radiotherapy in patients on progression after ipilimumab 3 mg/kg
2016
·
A.M. Grimaldi
, P.A. Ascierto
, et al.
·
Radiotherapy and Oncology
·
1
PDF
High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab
2014
·
Ester Simeone
, Maria fiammetta Romano
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Abstract 6957: Triple Immune Checkpoint Blockade Induces Immune-Mediated Cardiomyocyte Injury Through PCSK9 and NLRP3 Pathways: Translational Implications for Cardio-Oncology Surveillance
2026
·
Nicola Maurea
, Margherita Passariello
, et al.
·
Circulation
Show more works
View as search
Works count:
45
Citation count:
1,545
H-index:
10
I10-index:
10
Year
Topic
Type